Information Provided By:
Fly News Breaks for September 3, 2019
HCP
Sep 3, 2019 | 04:56 EDT
Stifel analyst Chad Vanacore raised his price target for HCP to $37 from $34 saying he sees the current macro environment as supportive of accelerating growth and a premium valuation. Large cap healthcare real estate investment trust prove to be increasingly attractive on yield and safety to generalist investors, Vanacore tells investors in a research note. He reiterates a Buy rating on HCP shares.